GSK's Cervarix Two-Dose Vaccine Schedule Approved in China

 GSK PLC said Friday that China has approved a two-dose schedule for its Cervarix vaccine for girls aged nine to 14.

The healthcare company said that the vaccine is against certain types of cancer-causing human papillomavirus. In 2020, there were 110,000 new cases of cervical cancer and 59,000 deaths due to the disease in China, it said.

The authorization of the two-dose regime by the Chinese regulator adds to approvals in around 100 countries. The three-dose schedule remains on the label for girls and women aged 15-45 years in China, GSK said.

https://www.marketscreener.com/quote/stock/GLAXOSMITHKLINE-PLC-9590199/news/GSK-s-Cervarix-Two-Dose-Vaccine-Schedule-Approved-in-China-40560107/